BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $220

Benzinga · 10/17 13:51
BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:ABBV) with a Outperform and raises the price target from $214 to $220.